As per the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry, “TAVR volume (72,991) exceeded all forms of surgical aortic valve replacement (SAVR) volume (57,626) for the first time in 2019. In 2019, it was estimated that 56% of the males underwent TAVR in the United States”.
As per the DelveInsight, the Transcatheter Aortic Valve Replacement (TAVR) Market is expected to see growth as the FDA expanded the indication for the use of TAVR to low-risk patients for death or have significant complications associated with open-heart surgery.
Some of the key pharmaceutical companies in the TAVR market include Medtronic, Boston Scientific, Edwards Lifesciences, Abbott, JenaValve Technology, Bracco, Transcatheter Technologies, JC Medical, and NV TAG, among others.
For more details, visit: Transcatheter Aortic Valve Replacement (TARV) Market Analysis